Vertex stock slips 3% as insiders flag sales, even as Alyftrek wins Australia funding
New York, Feb 17, 2026, 15:48 EST — Regular session Shares of Vertex Pharmaceuticals Incorporated slid roughly 3% on Tuesday, with traders reacting to a mix of analyst updates and fresh insider sale disclosures. By the afternoon, the stock was off 3.2% at $475.84.